Aravive Investor Presentation Deck
Market Research Suggests Batiraxcept Would Fill an Unmet
Need and Be Adopted into the Current ccRCC Treatment
Paradigm
Improved 2L
Efficacy over
Cabozantinib
Targeted
Therapy and
Novel MOA
2L Unmet Need
Improved efficacy over cabozantinib was seen as practice-
changing and may lead to less 1L cabo use in order to
preserve for 2L
Batiraxcept's biomarker-driven MOA was met with
enthusiasm given current lack of targeted approaches in
CCRCC
Batiraxcept is expected to gain meaningful 2L use due to
lack of established options within 2L
The upside efficacy would be practice-
changing in 2L...I would offer it to most of
the biomarker positive population." - KOL
"If this product actually
achieves this upside efficacy, I
would definitely wait to use
cabo with this product in the
2L."- KOL
Note: physicians' comments based on P1b data
27View entire presentation